HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sephora Settles California Consumer Privacy Suit; Beauty Retail News

Executive Summary

“My office is watching, and we will hold you accountable,” says California’s attorney in a 24 August release announcing settlement with Sephora over alleged violations of the state’s Consumer Privacy Act. More beauty retail news.

You may also be interested in...



Revlon Says Bankruptcy Filing Will Unlock Brand Power, Set Firm On Clearer Path

Revlon Inc. has filed for Chapter 11 protection after supply chain challenges, including disgruntled vendors, tipped the scale for the already struggling firm.

L’Oreal, Estee Lauder Virtual Try-On Tools Captured User Biometrics Without Consent – Plaintiff

Biometric litigation has been stacking up in state and federal courts, including suits targeting cosmetics companies for alleged consumer privacy violations associated with virtual try-on tools. L’Oreal and The Estee Lauder Companies are among the latest to be hit with proposed class actions in Illinois federal court.

US Interim Funding Bill Gets Biden’s Signature; Window Narrows For Cosmetics, Dietary Supplement Legislation

Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs. Policy riders stripped from the legislation, including for cosmetics and dietary supplement regulatory changes, could still find their way into a final FY 2023 spending omnibus.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel